Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole
Version of Record online: 10 AUG 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 68, Issue 5, pages 737–742, November 2009
How to Cite
Abdel-tawab, A. M., Bradley, M., Ghazaly, E. A., Horton, J. and El-Setouhy, M. (2009), Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. British Journal of Clinical Pharmacology, 68: 737–742. doi: 10.1111/j.1365-2125.2009.03524.x
- Issue online: 6 NOV 2009
- Version of Record online: 10 AUG 2009
- Received 14 July 2008Accepted31 July 2009
- albendazole sulphoxide;
- breast milk;
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Albendazole is used in several anthelminthic drug programs.
• It may be necessary to include sectors of the community (such as breastfeeding women) not previously involved in community or clinical programmes (e.g. filariasis, hydatid disease) to achieve a reasonable level of elimination of the worm.
• However, there are no studies in which the amount of the drug and/or its metabolites in the milk of lactating women was analysed, so as to assess the possible exposure of the breastfed infant.
WHAT THIS STUDY ADDS
• In the present study, the concentrations of albendazole and its active metabolite (albendazole sulphoxide) were analysed in the milk of lactating women through 36 h after administration of a single (400 mg) oral dose of albendazole.
• Albendazole was barely secreted in milk as such.
• On the other hand, albendazole sulphoxide was analysed through the 36 h of the study, and it was concluded that albendazole and albendazole sulphoxide attain levels in breast milk that are unlikely to be considered harmful for the breastfed infant.
• These findings would help in deciding whether to involve breastfeeding mothers in albendazole mass drug administration programmes.
Albendazole (ABZ) is used in several anthelminthic drug programmws. ABZ side-effects are generally mild, but ABZ-induced pancytopenia may be serious. In filariasis programmes, it may be necessary to administer ABZ to breastfeeding women. Few data are available on safety of ABZ for breastfed infants. In addition, the pharmacokinetics of ABZ and its metabolites in human milk is insufficiently investigated. The aim was to study pharmacokinetics of ABZ and its metabolites [ABZ sulphoxide (ABSX) and ABZ sulphone] in the breast milk lactating women after one single oral dose of ABZ.
Thirty-three lactating women (age 18–40 years) participated in the study. They received a single oral 400-mg dose of ABZ. Five milk samples were taken at 0, 6, 12, 24 and 36 h. One serum sample was taken after 6 h. Samples were analysed using high-performance liquid chromatography and pharmacokinetic analysis was performed.
ABZ was detectable in milk samples 6 h after the oral dose. The mean concentration of serum ABZ was 63.7 ± 11.9 ng ml−1. The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 ± 32.4 ng ml−1, 6.9 ± 0.5 h, 12.4 ± 2.2 h and 5190.3 ± 482.8 ng*h ml−1 for Cmax, Tmax, t½ and AUC0–36, respectively. The milk-to-serum ratios (range) for ABZ and ABSX were 0.9 (0.2–6.5) and 0.6 (0.1–1.5), respectively.
After an oral dose of 400 mg, ABZ and ABSX attain low concentrations in breast milk that are unlikely to be considered harmful for the breastfed infant.